Cohn P F
Department of Medicine, State University of New York Health Sciences Center, Stony Brook 11794-8171.
Clin Cardiol. 1994 Aug;17(8):415-21. doi: 10.1002/clc.4960170803.
Despite the introduction of new mechanical techniques for revascularization, pharmacologic therapy continues to be the mainstay of antianginal therapy. The conventional antianginal medications, which include nitrates, beta blockers, and calcium channel blockers, act to correct the imbalance between myocardial supply and demand by increasing coronary blood flow, reducing myocardial oxygen requirements, or both. All three are appropriate for the management of angina caused by a fixed coronary obstruction, but nitrates and calcium channel blockers, which not only reduce demand but also increase supply, are preferred in cases of angina believed to involve a significant increase in vasomotor tone. Because of the different yet complementary mechanisms of action of the three classes of anti-ischemic drugs, use of these agents in combination is a rational approach to the treatment of angina unresponsive to monotherapy. Such combinations have been shown to enhance the therapeutic response achieved with single-agent therapy. In addition, the pharmacologic action of one of the components of the combination regimen may serve to offset side effects typically associated with the other.
尽管引入了新的血管重建机械技术,但药物治疗仍然是抗心绞痛治疗的主要手段。传统的抗心绞痛药物,包括硝酸盐、β受体阻滞剂和钙通道阻滞剂,通过增加冠状动脉血流量、降低心肌需氧量或两者兼而有之,来纠正心肌供需之间的失衡。这三种药物都适用于治疗由固定冠状动脉阻塞引起的心绞痛,但硝酸盐和钙通道阻滞剂不仅能降低需求,还能增加供应,在认为涉及血管运动张力显著增加的心绞痛病例中更受青睐。由于这三类抗缺血药物的作用机制不同但相互补充,联合使用这些药物是治疗对单一疗法无反应的心绞痛的合理方法。已证明这种联合用药可增强单药治疗的疗效。此外,联合治疗方案中一种成分的药理作用可能有助于抵消通常与另一种成分相关的副作用。